Showing results (11-20 of 212) with videos related to

Sort By:
Pageof 22
The Journal of Organic Chemistry|March 16, 2002
Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugsBrian E Toki, Charles G Cerveny, Alan F Wahl, et al.
Methods in Enzymology|January 3, 2012
Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residuesRobert P Lyon, David L Meyer, Jocelyn R Setter, et al.
Nature Reviews. Drug Discovery|June 12, 2023
Antibody-drug conjugates come of age in oncologyCharles Dumontet, Janice M Reichert, Peter D Senter, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2002
Reductively activated disulfide prodrugs of paclitaxelVivekananda M Vrudhula, John F MacMaster, Zhengong Li, et al.
Molecular Pharmaceutics|April 19, 2005
Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9Toni Kline, Michael Y Torgov, Brian A Mendelsohn, et al.
Bioconjugate Chemistry|May 19, 2005
Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugateMichael Y Torgov, Stephen C Alley, Charles G Cerveny, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion proteinVivekananda M Vrudhula, David E Kerr, Nathan O Siemers, et al.
Cancer Research|April 17, 2004
Efficient cancer therapy with a nanobody-based conjugateVirna Cortez-Retamozo, Natalija Backmann, Peter D Senter, et al.
Bioconjugate Chemistry|July 22, 2004
Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathwayKerry Klussman, Bruce J Mixan, Charles G Cerveny, et al.
Molecular Pharmaceutics|August 9, 2007
Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivativeKai Temming, Damon L Meyer, Roger Zabinski, et al.
Pageof 22